CPhI Online

- Market News

Mylan launches first bioequivalent alternative to Advair Diskus in Canada

10 Mar 2020

Myland Pharmaceuticals' Wixela Inhub.

Appropriate asthma and COPD patients provided with a "more affordable alternative to appropriate".

Mylan Pharmaceuticals has launched Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) — the first available bioequivalent alternative to GSK's Advair Diskus in Canada.

Advair Diskus is a leading treatment for asthma and chronic obstructive pulmonary disease (COPD) management. According to IQVIA, it had Canadian sales of $113.9 million for the 12 months ending 31 December 2019.

Wixela Inhub is a dry powder inhaler and is the result of $700 million investment worldwide, including an extensive research and development program. It was approved by Health Canada in January for the twice-daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.

For asthma patients, Wixela Inhub is available in 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths, whereas for COPD patients, it is available in 250 mcg/50 mcg and 500 mcg/50 mcg strengths.

With today's launch in Canada, Mylan Canada Country Manager David Simpson commented: "We are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients."

Read More

Related Categories

Related Content